$RPRX
Royalty Pharma plc

2023 Q3 Form 10-Q Financial Statement

#000180276823000029 Filed on November 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3
Revenue $536.3M
YoY Change -6.48%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $57.20M
YoY Change 12.84%
% of Gross Profit
Research & Development $50.50M
YoY Change 98.04%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $50.50M
YoY Change 98.04%
Operating Profit $151.4M
YoY Change -21.21%
Interest Expense $46.03M
YoY Change -2.01%
% of Operating Profit 30.4%
Other Income/Expense, Net -$29.37M
YoY Change -204.12%
Pretax Income $122.1M
YoY Change -44.61%
Income Tax $0.00
% Of Pretax Income 0.0%
Net Earnings $72.11M
YoY Change -49.45%
Net Earnings / Revenue 13.45%
Basic Earnings Per Share $0.16
Diluted Earnings Per Share $0.16
COMMON SHARES
Basic Shares Outstanding 448.4M shares
Diluted Shares Outstanding 601.1M shares

Balance Sheet

Concept 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $941.7M
YoY Change -32.78%
Cash & Equivalents $936.4M
Short-Term Investments $5.300M
Other Short-Term Assets $6.784M
YoY Change -92.51%
Inventory
Prepaid Expenses
Receivables $16.00M
Other Receivables $22.00M
Total Short-Term Assets $1.729B
YoY Change -26.19%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $378.3M
YoY Change -7.7%
Other Assets $20.21M
YoY Change -33.98%
Total Long-Term Assets $14.13B
YoY Change -7.85%
TOTAL ASSETS
Total Short-Term Assets $1.729B
Total Long-Term Assets $14.13B
Total Assets $15.86B
YoY Change -10.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.00M
YoY Change -13.11%
Accrued Expenses $13.00M
YoY Change -1.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $127.9M
YoY Change -88.69%
LONG-TERM LIABILITIES
Long-Term Debt $6.131B
YoY Change 0.27%
Other Long-Term Liabilities $11.00M
YoY Change 11.11%
Total Long-Term Liabilities $6.131B
YoY Change 0.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $127.9M
Total Long-Term Liabilities $6.131B
Total Liabilities $6.270B
YoY Change -13.59%
SHAREHOLDERS EQUITY
Retained Earnings $2.135B
YoY Change -14.78%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.624M
YoY Change -5.88%
Treasury Stock Shares
Shareholders Equity $6.139B
YoY Change
Total Liabilities & Shareholders Equity $15.86B
YoY Change -10.28%

Cashflow Statement

Concept 2023 Q3
OPERATING ACTIVITIES
Net Income $72.11M
YoY Change -49.45%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities $573.5M
YoY Change 6.43%
INVESTING ACTIVITIES
Capital Expenditures $451.1M
YoY Change -134.27%
Acquisitions
YoY Change
Other Investing Activities $500.0K
YoY Change -100.46%
Cash From Investing Activities -$450.6M
YoY Change -68.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $1.000B
YoY Change
Cash From Financing Activities -1.360B
YoY Change 490.87%
NET CHANGE
Cash From Operating Activities 573.5M
Cash From Investing Activities -450.6M
Cash From Financing Activities -1.360B
Net Change In Cash -1.237B
YoY Change 10.77%
FREE CASH FLOW
Cash From Operating Activities $573.5M
Capital Expenditures $451.1M
Free Cash Flow $122.4M
YoY Change -93.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Trading Securities Debt
TradingSecuritiesDebt
0 usd
CY2022Q4 rprx Accrued Royalty Receivable
AccruedRoyaltyReceivable
16830000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
5300000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1300000 usd
CY2023Q3 rprx Other Royalty Income Receivable Current
OtherRoyaltyIncomeReceivableCurrent
21553000 usd
CY2022Q4 rprx Other Royalty Income Receivable Current
OtherRoyaltyIncomeReceivableCurrent
19767000 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
6784000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
90520000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
1728605000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
2554908000 usd
CY2023Q3 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
13230474000 usd
CY2022Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
13493106000 usd
CY2023Q3 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
144342000 usd
CY2022Q4 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
112348000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
353600000 usd
CY2022Q4 us-gaap Other Liabilities
OtherLiabilities
2500000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
6270427000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
7288093000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 rprx Deferred Shares Par Or Stated Value Per Share
DeferredSharesParOrStatedValuePerShare
0.000001
CY2023Q3 rprx Deferred Shares Par Or Stated Value Per Share
DeferredSharesParOrStatedValuePerShare
0.000001
CY2022Q4 rprx Deferred Shares Shares Outstanding
DeferredSharesSharesOutstanding
371325000 shares
CY2022Q4 rprx Deferred Shares Shares Issued
DeferredSharesSharesIssued
371325000 shares
CY2023Q3 rprx Deferred Shares Value Issued
DeferredSharesValueIssued
0 usd
CY2022Q4 rprx Deferred Shares Value Issued
DeferredSharesValueIssued
0 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4006758000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3666160000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2134680000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1964689000 usd
CY2023Q3 us-gaap Minority Interest
MinorityInterest
3446175000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
3897223000 usd
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
2624000 usd
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2806000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9585097000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9525373000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15855524000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16813466000 usd
CY2023Q3 us-gaap Revenues
Revenues
536313000 usd
CY2022Q3 us-gaap Revenues
Revenues
573463000 usd
us-gaap Revenues
Revenues
1758486000 usd
us-gaap Revenues
Revenues
1671467000 usd
CY2023Q3 us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
277137000 usd
CY2022Q3 us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
305061000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
126606000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5670000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
57234000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
46977000 usd
us-gaap Interest Expense
InterestExpense
139932000 usd
CY2023Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-8680000 usd
CY2022Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
25785000 usd
CY2023Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
1541000 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
97985000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
65791000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
34482000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10798000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3429000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13590000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-29365000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
28204000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
103248000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
50374000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
220414000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
982502000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
840094000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
122077000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
220414000 usd
us-gaap Profit Loss
ProfitLoss
982502000 usd
us-gaap Profit Loss
ProfitLoss
840094000 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
49963000 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
77763000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
342008000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
341178000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
72114000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
142651000 usd
us-gaap Net Income Loss
NetIncomeLoss
640494000 usd
us-gaap Net Income Loss
NetIncomeLoss
498916000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.14
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.14
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
448439000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
448162000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
436542000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
601138000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607226000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
604717000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607209000 shares
CY2023Q3 us-gaap Profit Loss
ProfitLoss
122077000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
220414000 usd
us-gaap Profit Loss
ProfitLoss
982502000 usd
us-gaap Profit Loss
ProfitLoss
840094000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
13050000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
24000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
7111000 usd
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
24053000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5939000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
341109000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
72114000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
146192000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
640494000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
498932000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9813686000 usd
CY2023Q3 rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
2850000 usd
CY2023Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
120198000 usd
CY2023Q3 us-gaap Dividends Cash
DividendsCash
89751000 usd
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
144148000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
122077000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9585097000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10408187000 usd
CY2022Q3 rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
2970000 usd
CY2022Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
137880000 usd
CY2022Q3 us-gaap Dividends Cash
DividendsCash
83809000 usd
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
278629000 usd
us-gaap Profit Loss
ProfitLoss
982502000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9585097000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10248545000 usd
rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
9173000 usd
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
433822000 usd
us-gaap Dividends Cash
DividendsCash
249121000 usd
us-gaap Stockholders Equity Other
StockholdersEquityOther
0 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1587000 usd
us-gaap Profit Loss
ProfitLoss
840094000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
24000000 usd
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
24053000 usd
rprx Proceeds From Cash Collections From Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
2454054000 usd
rprx Proceeds From Cash Collections From Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
1843899000 usd
rprx Proceeds From Cash Collections From Royalties Received On Intangible Assets
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
1067000 usd
rprx Proceeds From Cash Collections From Royalties Received On Intangible Assets
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
72406000 usd
rprx Proceeds From Cash Collections From Other Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
84275000 usd
rprx Proceeds From Cash Collections From Other Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
51607000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
18823000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
33316000 usd
rprx Payments For Ongoing Development Stage Funding
PaymentsForOngoingDevelopmentStageFunding
1500000 usd
rprx Payments For Ongoing Development Stage Funding
PaymentsForOngoingDevelopmentStageFunding
1606000 usd
rprx Payments For Upfront Development Stage Funding
PaymentsForUpfrontDevelopmentStageFunding
50000000 usd
rprx Payments For Upfront Development Stage Funding
PaymentsForUpfrontDevelopmentStageFunding
125000000 usd
rprx Payments For Operating Costs And Professional Services
PaymentsForOperatingCostsAndProfessionalServices
188839000 usd
rprx Payments For Operating Costs And Professional Services
PaymentsForOperatingCostsAndProfessionalServices
141653000 usd
us-gaap Interest Paid Net
InterestPaidNet
165841000 usd
us-gaap Interest Paid Net
InterestPaidNet
169476000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2215174000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1574049000 usd
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
39225000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
9896000 usd
rprx Payments To Acquire Equity Securities Fnni
PaymentsToAcquireEquitySecuritiesFNNI
0 usd
rprx Payments To Acquire Equity Securities Fnni
PaymentsToAcquireEquitySecuritiesFNNI
62785000 usd
CY2022Q4 us-gaap Trading Securities Debt
TradingSecuritiesDebt
24421000 usd
CY2023Q3 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
742160000 usd
CY2022Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
691319000 usd
CY2023Q3 rprx Accrued Royalty Receivable
AccruedRoyaltyReceivable
16360000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
226300000 usd
CY2023Q3 us-gaap Equity Method Investments
EquityMethodInvestments
378291000 usd
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
397175000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20212000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
29629000 usd
CY2023Q3 us-gaap Assets
Assets
15855524000 usd
CY2022Q4 us-gaap Assets
Assets
16813466000 usd
CY2023Q3 rprx Distributions Payable To Legacy Non Controlling Interests Current
DistributionsPayableToLegacyNonControllingInterestsCurrent
101711000 usd
CY2022Q4 rprx Distributions Payable To Legacy Non Controlling Interests Current
DistributionsPayableToLegacyNonControllingInterestsCurrent
94803000 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13627000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7906000 usd
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
12595000 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
54162000 usd
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
997512000 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12400000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
127933000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1166783000 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6131194000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6118810000 usd
CY2023Q3 us-gaap Other Liabilities
OtherLiabilities
11300000 usd
CY2023Q3 rprx Deferred Shares Shares Outstanding
DeferredSharesSharesOutstanding
382837000 shares
CY2023Q3 rprx Deferred Shares Shares Issued
DeferredSharesSharesIssued
382837000 shares
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
637169000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
595396000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50500000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25500000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51500000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50692000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
190563000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
154075000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
384871000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
381253000 usd
us-gaap Costs And Expenses
CostsAndExpenses
879232000 usd
us-gaap Costs And Expenses
CostsAndExpenses
881747000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
151442000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
192210000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
879254000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
789720000 usd
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-5222000 usd
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-3251000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
28614000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2117000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
46033000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
122077000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.43
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
439293000 shares
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-53000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
122077000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
226353000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
982502000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
840041000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
49963000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
80161000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
342008000 usd
CY2023Q3 us-gaap Stockholders Equity Other
StockholdersEquityOther
0 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
581000 usd
CY2023Q3 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
4862000 shares
CY2022Q3 us-gaap Stockholders Equity Other
StockholdersEquityOther
0 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
582000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
220414000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
13050000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
7111000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10416403000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9525373000 usd
rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
9690000 usd
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
386590000 usd
us-gaap Dividends Cash
DividendsCash
268989000 usd
us-gaap Stockholders Equity Other
StockholdersEquityOther
0 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1740000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10416403000 usd
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
63135000 usd
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
10556000 usd
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
0 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
10550000 usd
rprx Proceeds From Issuance Of Equity Securities Fnni
ProceedsFromIssuanceOfEquitySecuritiesFNNI
0 usd
rprx Proceeds From Issuance Of Equity Securities Fnni
ProceedsFromIssuanceOfEquitySecuritiesFNNI
46158000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
393737000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
46875000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
234869000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
24391000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
676705000 usd
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
1113283000 usd
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
1491399000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
21215000 usd
rprx Payments For Milestones
PaymentsForMilestones
12400000 usd
rprx Payments For Milestones
PaymentsForMilestones
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1072617000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1444163000 usd
rprx Payments To Noncontrolling Interests Royalty Receipts
PaymentsToNoncontrollingInterestsRoyaltyReceipts
284637000 usd
rprx Payments To Noncontrolling Interests Royalty Receipts
PaymentsToNoncontrollingInterestsRoyaltyReceipts
322726000 usd
rprx Payments To Noncontrolling Interests Other
PaymentsToNoncontrollingInterestsOther
0 usd
rprx Payments To Noncontrolling Interests Other
PaymentsToNoncontrollingInterestsOther
2335000 usd
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
95045000 usd
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
110964000 usd
rprx Payment Of Dividends To Shareholders
PaymentOfDividendsToShareholders
268989000 usd
rprx Payment Of Dividends To Shareholders
PaymentOfDividendsToShareholders
249121000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
274559000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
rprx Proceeds From Noncontrolling Interests Research And Development
ProceedsFromNoncontrollingInterestsResearchAndDevelopment
455000 usd
rprx Proceeds From Noncontrolling Interests Research And Development
ProceedsFromNoncontrollingInterestsResearchAndDevelopment
971000 usd
rprx Proceeds From Noncontrolling Interests Other
ProceedsFromNoncontrollingInterestsOther
5915000 usd
rprx Proceeds From Noncontrolling Interests Other
ProceedsFromNoncontrollingInterestsOther
4869000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1000000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1916860000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-679306000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-774303000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-549420000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1710751000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1541048000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
936448000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
991628000 usd
us-gaap Use Of Estimates
UseOfEstimates
The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year.
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
Certain prior period amounts have been reclassified to conform to the current period presentation.
CY2023Q3 us-gaap Notes Receivable Gross
NotesReceivableGross
17114292000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale debt securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of September 30, 2023 and December 31, 2022 were held with Bank of America, State Street, Scotiabank, Citibank, TD Bank, DNB Bank and U.S. Bank. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson &amp; Johnson, Merck &amp; Co., Pfizer, Astellas, Novartis and Gilead. As of September 30, 2023 and December 31, 2022, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, represented the largest individual marketer and payor of our royalties, accounting for 31% of our current portion of financial royalty assets.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.</span></div>
CY2022Q1 rprx Long Term Funding Partnership Amount
LongTermFundingPartnershipAmount
300000000 usd
CY2022Q1 rprx Long Term Funding Partnership Number Of Tranches
LongTermFundingPartnershipNumberOfTranches
5 tranche
CY2022Q1 rprx Long Term Funding Partnership Initial Payment
LongTermFundingPartnershipInitialPayment
50000000 usd
CY2022Q1 rprx Long Term Funding Partnership Covenant Required Amount
LongTermFundingPartnershipCovenantRequiredAmount
50000000 usd
CY2022Q1 rprx Long Term Funding Partnership Additional Payments Aggregate Amount
LongTermFundingPartnershipAdditionalPaymentsAggregateAmount
200000000 usd
CY2022Q1 rprx Long Term Funding Partnership Optional Amount Unavailable
LongTermFundingPartnershipOptionalAmountUnavailable
75000000 usd
CY2022Q1 rprx Long Term Funding Partnership Installment Repayments Amount Drawn Multiple
LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple
1.9
CY2022Q1 rprx Number Of Consecutive Quarterly Payments
NumberOfConsecutiveQuarterlyPayments
34 payment
rprx Long Term Funding Partnership Expected Payment
LongTermFundingPartnershipExpectedPayment
125000000 usd
CY2022Q1 rprx Long Term Funding Partnership Additional Payments Aggregate Amount
LongTermFundingPartnershipAdditionalPaymentsAggregateAmount
200000000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
352100000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4500000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
347600000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
5300000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
353600000 usd
CY2023Q3 rprx Debt Securities Available For Sale Liability Noncurrent
DebtSecuritiesAvailableForSaleLiabilityNoncurrent
11300000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
347600000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
350000000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
124900000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
225100000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1300000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
226300000 usd
CY2022Q4 rprx Debt Securities Available For Sale Liability Noncurrent
DebtSecuritiesAvailableForSaleLiabilityNoncurrent
2500000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
225100000 usd
CY2022 rprx Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag
fair value
rprx Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleListNotDisclosedFlag
fair value
CY2023Q3 us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
1500000 usd
us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
32000000 usd
CY2022Q3 us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
-900000 usd
us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
-27700000 usd
CY2023Q3 rprx Financing Receivable Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
2994831000 usd
CY2023Q3 rprx Financing Receivables After Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
14119461000 usd
CY2023Q3 rprx Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal
FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
146827000 usd
CY2023Q3 us-gaap Notes Receivable Net
NotesReceivableNet
13972634000 usd
CY2023Q3 us-gaap Notes Receivable Net
NotesReceivableNet
14000000000 usd
CY2022Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
16776307000 usd
CY2022Q4 rprx Financing Receivable Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
2476460000 usd
CY2022Q4 rprx Financing Receivables After Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
14299847000 usd
CY2022Q4 rprx Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal
FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
115422000 usd
CY2022Q4 us-gaap Notes Receivable Net
NotesReceivableNet
14184425000 usd
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
2591882000 usd
rprx Financing Receivable Change In Present Value Decreases To Cumulative Allowance Reversal Of Expense
FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense
-860242000 usd
us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
254478000 usd
rprx Financing Receivable Change In Present Value Write Off Cumulative Allowance
FinancingReceivableChangeInPresentValueWriteOffCumulativeAllowance
87393000 usd
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
31405000 usd
CY2023Q3 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
3141658000 usd
CY2022Q4 rprx Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal
FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
115400000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50500000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51500000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25500000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
126600000 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
168806000 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
183678000 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
6131194000 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
7116322000 usd
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
997512000 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6131194000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6118810000 usd
CY2023Q3 rprx Number Of Classes Of Voting Stock
NumberOfClassesOfVotingStock
2 class
CY2023Q3 rprx Common Stock Voting Rights Number Of Votes
CommonStockVotingRightsNumberOfVotes
1 vote
CY2023Q3 rprx Common Stock Quarterly Conversion Basis
CommonStockQuarterlyConversionBasis
1 shares
CY2022Q3 rprx Number Of Noncontrolling Interests
NumberOfNoncontrollingInterests
4 noncontrolling_interest
CY2023Q3 rprx Number Of Noncontrolling Interests
NumberOfNoncontrollingInterests
4 noncontrolling_interest
rprx Share Based Compensation Arrangement By Share Based Payment Award Covenant Percentage Of Net Economic Profit
ShareBasedCompensationArrangementByShareBasedPaymentAwardCovenantPercentageOfNetEconomicProfit
0.20
rprx Number Of Dividend Payments
NumberOfDividendPayments
3 payment
us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.20
rprx Payment Of Dividends To Shareholders
PaymentOfDividendsToShareholders
269000000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P1Y
CY2023Q3 us-gaap Profit Loss
ProfitLoss
122077000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
220414000 usd
us-gaap Profit Loss
ProfitLoss
982502000 usd
us-gaap Profit Loss
ProfitLoss
840094000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
72114000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
142651000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
640494000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
498916000 usd
CY2023Q3 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
24055000 usd
CY2022Q3 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
54396000 usd
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
225361000 usd
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
194281000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
96169000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
197047000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
865855000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
693197000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
448439000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
439293000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
448162000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
436542000 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
152691000 shares
CY2022Q3 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
167927000 shares
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
156541000 shares
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
170651000 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8000 shares
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
6000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
14000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
16000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
601138000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607226000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
604717000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607209000 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.14
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.14
us-gaap Profit Loss
ProfitLoss
982502000 usd
us-gaap Profit Loss
ProfitLoss
840094000 usd
rprx Increase Decrease In Financial Royalty Assets
IncreaseDecreaseInFinancialRoyaltyAssets
1674689000 usd
rprx Increase Decrease In Financial Royalty Assets
IncreaseDecreaseInFinancialRoyaltyAssets
1578555000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
637169000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
595396000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5670000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
15658000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
16026000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-2290000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
97590000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
31994000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-22970000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
28614000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2117000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
18823000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
33316000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1740000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1587000 usd
rprx Investment Income Net Reclassification Of Available For Sale Debt Securities Gain Loss
InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss
0 usd
rprx Investment Income Net Reclassification Of Available For Sale Debt Securities Gain Loss
InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss
24053000 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
122500000 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
97985000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3263000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3443000 usd
rprx Increase Decrease In Cash Collections On Financing Receivables
IncreaseDecreaseInCashCollectionsOnFinancingReceivables
2454054000 usd
rprx Increase Decrease In Cash Collections On Financing Receivables
IncreaseDecreaseInCashCollectionsOnFinancingReceivables
1843899000 usd
rprx Increase Decrease In Accrued Royalty Receivable
IncreaseDecreaseInAccruedRoyaltyReceivable
-470000 usd
rprx Increase Decrease In Accrued Royalty Receivable
IncreaseDecreaseInAccruedRoyaltyReceivable
-37574000 usd
rprx Increase Decrease In Other Royalty Income Receivable
IncreaseDecreaseInOtherRoyaltyIncomeReceivable
669000 usd
rprx Increase Decrease In Other Royalty Income Receivable
IncreaseDecreaseInOtherRoyaltyIncomeReceivable
4108000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
2412000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-8253000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1650000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
10492000 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-41567000 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-44497000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2215174000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1574049000 usd
rprx Long Term Funding Partnership Expected Payment
LongTermFundingPartnershipExpectedPayment
125000000 usd
CY2022Q1 rprx Long Term Funding Partnership Additional Payments Aggregate Amount
LongTermFundingPartnershipAdditionalPaymentsAggregateAmount
200000000 usd
CY2022Q1 rprx Long Term Funding Partnership Covenant Required Amount
LongTermFundingPartnershipCovenantRequiredAmount
50000000 usd
CY2023Q3 rprx Distributions Payable To Legacy Non Controlling Interests Current
DistributionsPayableToLegacyNonControllingInterestsCurrent
101711000 usd
CY2022Q4 rprx Distributions Payable To Legacy Non Controlling Interests Current
DistributionsPayableToLegacyNonControllingInterestsCurrent
94803000 usd
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001802768-23-000029-index-headers.html Edgar Link pending
0001802768-23-000029-index.html Edgar Link pending
0001802768-23-000029.txt Edgar Link pending
0001802768-23-000029-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rprx-20230930.htm Edgar Link pending
rprx-20230930.xsd Edgar Link pending
rprx-20230930ex311.htm Edgar Link pending
rprx-20230930ex312.htm Edgar Link pending
rprx-20230930ex32.htm Edgar Link pending
Show.js Edgar Link pending
rprx-20230930_cal.xml Edgar Link unprocessable
rprx-20230930_pre.xml Edgar Link unprocessable
rprx-20230930_htm.xml Edgar Link completed
rprx-20230930_lab.xml Edgar Link unprocessable
rprx-20230930_def.xml Edgar Link unprocessable